Hepatitis B virus X protein inhibits p53-mediated upregulation of mitofusin-2 in hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 421, Issue 2, 2012, Pages 355-360

  Wang, Weilin ^a   Zhou, Dongkai ^a   Wei, Jianfeng ^a   Wu, Zehui ^a   Cheng, Xiaofei ^b   Sun, Qiang ^a   Xie, Haiyang ^a   Zhou, Lin ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Doxorubicin; Hepatitis B virus X protein; Hepatocellular carcinoma; Mitofusin 2; P53

Indexed keywords

BETA ACTIN; DOXORUBICIN; HEPATITIS B VIRUS X PROTEIN; LUCIFERASE; MITOFUSIN 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ASSAY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP PHOSPHOHYDROLASES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MITOCHONDRIAL PROTEINS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

HEPATITIS B VIRUS;

EID: 84860469186     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.015     Document Type: Article

References (28)

1. Chen H., Detmer S.A., Ewald A.J., Griffin E.E., Fraser S.E., Chan D.C. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J. Cell Biol. 2003, 160:189-200.
2. Eura Y., Ishihara N., Oka T., Mihara K. Identification of a novel protein that regulates mitochondrial fusion by modulating mitofusin (Mfn) protein function. J. Cell Sci. 2006, 119:4913-4925.
3. Bach D., Naon D., Pich S., Soriano F.X., Vega N., Rieusset J., Laville M., Guillet C., Boirie Y., Wallberg-Henriksson H., Manco M., Calvani M., Castagneto M., Palacin M., Mingrone G., Zierath J.R., Vidal H., Zorzano A. Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. Diabetes 2005, 54:2685-2693.
4. Zuchner S., Mersiyanova I.V., Muglia M., Bissar-Tadmouri N., Rochelle J., Dadali E.L., Zappia M., Nelis E., Patitucci A., Senderek J., Parman Y., Evgrafov O., Jonghe P.D., Takahashi Y., Tsuji S., Pericak-Vance M.A., Quattrone A., Battaloglu E., Polyakov A.V., Timmerman V., Schroder J.M., Vance J.M. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet. 2004, 36:449-451.
5. Chen K.H., Guo X., Ma D., Guo Y., Li Q., Yang D., Li P., Qiu X., Wen S., Xiao R.P., Tang J. Dysregulation of HSG triggers vascular proliferative disorders. Nat. Cell Biol. 2004, 6:872-883.
6. Guo X., Chen K.H., Guo Y., Liao H., Tang J., Xiao R.P. Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway. Circ. Res. 2007, 101:1113-1122.
7. Karbowski M., Lee Y.J., Gaume B., Jeong S.Y., Frank S., Nechushtan A., Santel A., Fuller M., Smith C.L., Youle R.J. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J. Cell Biol. 2002, 159:931-938.
8. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
9. Lee S.G., Rho H.M. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene 2000, 19:468-471.
10. Takada S., Kaneniwa N., Tsuchida N., Koike K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 1997, 15:1895-1901.
11. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA 1994, 91:2230-2234.
12. Chung T.W., Lee Y.C., Ko J.H., Kim C.H. Hepatitis B Virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res. 2003, 63:3453-3458.
13. Xian L., Zhao J., Wang J., Fang Z., Peng B., Wang W., Ji X., Yu L. p53 Promotes proteasome-dependent degradation of oncogenic protein HBx by transcription of MDM2. Mol. Biol. Rep. 2010, 37:2935-2940.
14. Wang W., Cheng X., Lu J., Wei J., Fu G., Zhu F., Jia C., Zhou L., Xie H., Zheng S. Mitofusin-2 is a novel direct target of p53. Biochem. Biophys. Res. Commun. 2010, 400:587-592.
15. Wang W., Lu J., Zhu F., Wei J., Jia C., Zhang Y., Zhou L., Xie H., Zheng S. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells. Med. Oncol. 2012, 29:70-76.
16. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1992, 1:45-49.
17. Xie H.Y., Xia W.L., Zhang C.C., Wu L.M., Ji H.F., Cheng Y., Zheng S.S. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment. Acta. Pharmacol. Sin. 2007, 28:975-984.
18. Xie H.Y., Cheng J., Xing C.Y., Wang J.J., Su R., Wei X.Y., Zhou L., Zheng S.S. Evaluation of hepatitis B viral replication and proteomic analysis of HepG2.2.15 cell line after knockdown of HBx. Hepatobiliary Pancreat. Dis. Int. 2011, 10:295-302.
19. de Brito O.M., Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008, 456:605-610.
20. Merkwirth C., Langer T. Mitofusin 2 builds a bridge between ER and mitochondria. Cell 2008, 135:1165-1167.
21. Wang W., Zhu F., Wang S., Wei J., Jia C., Zhang Y., Zhou L., Xie H., Zheng S. HSG provides antitumor efficacy on hepatocellular carcinoma both in vitro and in vivo. Oncol. Rep. 2010, 24:183-188.
22. Gottlieb T.M., Oren M. P53 in growth control and neoplasia. Biochim. Biophys. Acta 1996, 1287:77-102.
23. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996, 10:1054-1072.
24. Keasler V.V., Hodgson A.J., Madden C.R., Slagle B.L. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J. Virol. 2007, 81:2656-2662.
25. Feitelson M.A., Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2007, 252:157-170.
26. Feitelson M.A., Reis H.M., Tufan N.L., Sun B., Pan J., Lian Z. Putative roles of hepatitis B×antigen in the pathogenesis of chronic liver disease. Cancer Lett. 2009, 286:69-79.
27. Ueda H., Ullrich S.J., Gangemi J.D., Kappel C.A., Ngo L., Feitelson M.A., Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 1995, 9:41-47.
28. Yun C., Lee J.H., Park H., Jin Y.M., Park S., Park K., Cho H. Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells. Oncogene 2000, 19:5163-5172.